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The formation of arachidonic acid-derived lipoxygenase products was examined with human granulocytes 
obtained from eosinophilic donors. These eosinophil-enriched leukocyte populations, challenged in vitro 
with the ionophore of divalent cations A23187, transformed both exogenous and endogenous ources of 
arachidonic acid to several lipoxygenase-derived products, including 5(5’),6(R),lS(S’)-trihydroxy-7,9,13- 
trans-1 I-cis-eicosatetraenoic acid (lipoxin A). Lipoxin A was detected and characterized by high-pressure 
liquid chromatography (HPLC), ultraviolet absorbance, and gas-liquid chromatography-mass pectrosco- 
py. Neither lipoxin B nor 6(S)-LXA was consistently detected in extracts from these incubations. The 
amounts of lipoxin A formed were proportional to the percentage of eosinophils present in the suspension. 
The results indicate that granulocytes from eosinophilic donors can generate lipoxin A. 
Lipoxygenase product; Eosinophil; Arachidonic acid; Leukocyte; (Human) 
1. INTRODUCTION 
The enzymatic oxygenation of non-esterified 
arachidonic acid by a wide variety of cell types 
results in the formation of several classes of bio- 
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logically active compounds [ 1,2]. Mammalian 
leukocytes possess lipoxygenases (5-, 12-, 15LO) 
which, when activated, commit non-esterified fatty 
acids such as arachidonate to highly specific 
metabolic routes of transformation [2]. Among 
these cell types the eosinophil, which is held to play 
an important role in both immune and hypersen- 
sitive reactions [3], can generate products of both 
the 5- and 1Slipoxygenase pathways [4-l I]. Un- 
like human neutrophils, which can generate leuko- 
triene Bq as a predominant 5-lipoxygenase-derived 
product, human eosinophils generate leukotriene 
Cd [6,8-111. These cells can also generate 15-lip- 
oxygenase-derived products, including 15-HETE, 
several 8,15-DHETE isomers, and a product of 
double dioxygenation (i.e. 5,15-DHETE) [5,7,9]. 
Recently, we have reported the isolation and 
complete structural characterization of several 
members of a novel series of tetraene-containing 
eicosanoids. These compounds, termed lipoxins, 
can be formed by interactions between the 5- and 
15-lipoxygenases [12,13]. Of this series, lipoxin A 
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and lipoxin B display stereospecific activities which 
include actions on human natural killer cells, 
neutrophils, microcirculation, lung strips, and 
isolated protein kinase C (Ca’+/phospholipid- 
dependent protein kinase) [ 13-171. In addition, 
one biosynthetic route in the formation of lipoxins 
and their isomers has been established [18,19]. 
Here we present evidence for the generation of 
lipoxin A by human eosinophil-rich granulocyte 
suspensions which were obtained from eosino- 
philic donors. 
2. MATERIALS AND METHODS 
2.1. Materials 
Arachidonic acid was purchased from Nu-Chek, 
MN and [l-14C]arachidonic acid from DuPont 
NEN (Boston, MA). Ionophore A23187 was from 
Sigma (St. Louis, MO). All solvents were of HPLC 
grade obtained from Rathburn Chemicals (Wal- 
kerburne). 
2.2. Cell preparations and incubations 
Four patients gave their consent to donate 
blood: one with eosinophilia from an allergic 
disorder, two from reactions to drugs, and one 
from the hypereosinophilic syndrome. Eosinophil- 
rich suspensions were prepared [9] with minor 
modifications. Heparinized blood (60 ml) was 
suspended in Percoll (Pharmacia, Upsala) (1.077 
g/cm3, pH 7.4) and centrifuged (400 xg, 5 min). 
Red cells in the pellets were lysed with ice-cold 
NH&l. In order to increase the difference in 
specific gravity between neutrophils and eosino- 
phils, washed granulocytes were incubated at 37°C 
for 30 min in Hank’s balanced salt solution 
(HBSS), containing 5% fetal calf serum, at pH 
7.0. Next, cells were pelleted and suspended in Per- 
co11 (1.082 g/cm3), layered over Percoll (1.100 
g/cm’) and centrifuged (20 min at 1000 xg). 
Eosinophils were recovered and smears showed 
that eosinophils were rarely detected in other cell 
fractions obtained during this process. Either 
arachidonic acid (final concentration 70-100 /IM) 
or l-‘4C-labeled arachidonic acid was added to cell 
suspensions along with A23187 (2.5 PM). In the 
next series of experiments cells were incubated with 
A23187 (2.5 pM) alone (20 min, 37°C). Incuba- 
tions were stopped after 20 min by addition of 2 
vols ice-cold methanol. PGB2 (50 ng) was added as 
an internal standard. 
2.3. Isolation and analytical methods 
Procedures for extraction and silicic acid chro- 
matography were as described [ 18,191, Briefly, 
fractions from silicic acid chromatography were 
evaporated, dissolved in methanol, treated with 
diazomethane and injected into a reverse-phase 
HPLC (RP-HPLC) column. In the HPLC system 
denoted as system A, the column (Nucleosil C18, 
4.6 mm x 25 cm) was eluted with methanol: water 
(65 : 45, v/v) at 1 .O ml/min; in system B the column 
(Altex, ultrasphere - ODS, 10 mmx25 cm) was 
eluted with methanol: water (65: 35, v/v) at 3.0 
ml/min. The presence of leukotriene C4 in these 
incubations was assessed by partial purification 
with Sep-pak@ Cl8 cartridges (Waters Associates, 
Milford, MA) followed by RP-HPLC analysis. 
Here, the column was eluted with acetonitrile: 
water (30:70, v/v), pH 5.7 at 1 ml/min with the 
UV detector set at 280 nm. The amounts of eico- 
sanoids were assessed by measuring peaks of 
authentic materials obtained with varying amounts 
in each HPLC system. Fractions were collected 
and UV spectra were recorded with a Hewlett- 
Packard model 8450A spectrophotometer. Sam- 
ples were converted to MesSi derivatives [20] and 
GC-MS was performed with a Dani 3800 gas 
chromatograph with a fused silica column SE-30 
(20 m x0.32 Orion) and a 7070EVG analytical 
mass spectrometer. 
3. RESULTS AND DISCUSSION 
When challenged in vitro, eosinophil-rich leuko- 
cyte suspensions obtained from peripheral blood 
of normal, bronchial asthmatic, and idiopathic 
hypereosinophilic syndrome (HES) donors gener- 
ate a variety of arachidonic acid derived-lipoxy- 
genase products [4-l 11. The results of these studies 
prompted us to examine whether human eosino- 
phils can generate tetraehe-containing eicosanoids. 
Here, eosinophil-rich leukocyte suspensions were 
prepared from eosinophilic donors and arachid- 
onic acid-derived lipoxygenase products formed 
upon activation were examined. In order to obtain 
quantities which would enable unambiguous iden- 
tification of products, eosinophil-rich leukocyte 
suspensions were first incubated with exogenous 
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arachidonic acid (70-100 PM), l-‘4C-labeled 
arachidonic acid (in some experiments), and the 
ionophore A23 187 (2.5 ,uM). Following extraction, 
silicic acid chromatography and treatment with 
diazomethane, samples were injected onto RP- 
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Fig.1. (A) RP-HPLC chromatogram of products 
obtained following incubation of a human eosinophil- 
rich granulocyte suspension with arachidonic acid (80 
PM) and ionophore A23187 (2SpM) for 20 min at 37°C. 
The granulocyte suspension (18 x lo6 cells/ml) contained 
74.5% eosinophils as determined by light microscopy 
following purification from blood. The sample was 
derived from a patient with the diagnosis of hyper- 
eosinophilic syndrome. The incubation was stopped with 
methanol and the products were extracted and chroma- 
tographed in RP-HPLC system A (section 2). (B) UV 
spectrum of material eluting beneath the peak denoted A 
in the chromatogram shown in panel A. This spectrum 
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Fig.2. Relationship between amounts of LXA formed by 
granulocytes from HES donors following incubation 
with ionophore A23187 (2.5 ,uM) for 20 min at 37°C and 
the number of eosinophils (o/o of total cell suspension) 
(r=0.9). Each point represents a separate cell 
purification. Values are expressed as LXA ng/30x lo6 
was recorded with methanol as solvent. cells per incubation. 
HPLC columns. In addition to products previous- 
ly identified [4-l 1,211 including 5,15-DHETE, 
8,15-DHETEs and LTG, a component showing 
strong absorption (while monitoring at 301 nm) 
was obtained. 
Material eluting beneath the peak denoted as A 
was collected, transferred, and analyzed. The UV 
spectrum showed a triplet of absorption’ bands at 
287, 300 and 315 nm (fig.1) consistent with that of 
a conjugated tetraene [12]. GC-MS analysis of the 
Me& derivative of this material gave a C value of 
24. The prominent ions in its mass spectrum were 
at m/e 379,289,203 (base peak), 173 and 171. Ions 
of lower intensity were at m/e 482, 492 and 582 M. 
Material from peak A also displayed the same 
retention time on RP-HPLC (system A) as that of 
the methyl ester of authentic lipoxin A. Thus, on 
the basis of these findings and by comaprison with 
published criteria [12,13,18,19] the identity of the 
material eluting under this peak iS lipoxin A. 
Neither lipoxin B nor 6(S)-LXA was consistently 
observed in extracts from these incubations; how- 
ever, LXB was identified and observed in amounts 
less than those of LXA in two samples. Other 
products in these extracts which were consistently 
observed and identified by comparison with pub- 
lished criteria [21] included 8,15-DHETE isomers 
(which eluted under the two prominent peaks 
80 - 
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following PGB2, fig.l), 5,15-DHETE (which 
eluted at a retention time of 50 min), and 
leukotriene C4 which was identified utilizing a 
separate isolation and HPLC solvent system (see 
section 2). It should be noted, however, that the 
8,15-DHETEs were not detectable in these extracts 
in the absence of exogenous arachidonic acid. 
We next examined the relationship between the 
amounts of LXA formed by eosinophil-rich 
leukocyte suspensions incubated with ionophore 
A23187 (2.5 PM) (without addition of exogenous 
arachidonic acid) and the percentage of eosino- 
phils present in these suspensions (fig.2). The 
values obtained for LXA are expressed per 30 x lo6 
leukocytes per incubation, since the mean value of 
cells (or total cell numb,er) obtained following 
isolation from whole blood was 30.9x lo6 cells. 
The amount of LXA formed by leukocytes cor- 
related with the percentage of eosinophils. This 
suggests that the formation of LXA from endo- 
genous sources in eosinophil-rich leukocyte sus- 
pensions, exposed to ionophore A23187, is 
proportional to the percentage of eosinophils pre- 
sent. It cannot, however, be concluded from these 
results whether LXA was formed exclusively from 
the arachidonic acid release and processed within a 
single cell. For example, transcellular metabolism 
or cell-cell interactions can contribute to the for- 
mation of various lipoxygenase-derived products 
[22-241. In particular, activated leukocytes can 
utilize exogenous 15-HETE to generate both lipox- 
in A and B [18,19]. It remains possible, then, that 
upon addition of A23187 to eosinophil-enriched 
cell suspensions suitable substrate(s) can be 
mobilized by one cell which can be utilized and 
transformed to lipoxin A by another. 
Previous studies have reported that leukotriene 
C4 is the predominant 5-lipozygenase pathway 
product generated by eosinophils [6,9-l 11. We 
have confirmed and extended these observations in 
the present study. When the values obtained for 
LTG formation by HES-derived leukocytes were 
compared to those obtained for LXA (with cells 
from the same patient) LTC4 was detected in 
amounts approx. 20-50-times greater than those of 
LXA. Also, the amounts of LTC4 observed from 
incubations examined in the present study were 
comparable to those reported [6-l 11, suggesting 
that eosinophils from these patient categories can 
generate LTC4 in amounts greater than LXA when 
exposed to ionophore A23 187. It has been demon- 
strated that subpopulations of eosinophils, par- 
ticularly those of low density obtained from 
patients with bronchial asthma during a quiescent 
state, can generate greater amounts of LTC4 than 
those of higher densities [l I]. It is not possible to 
conclude from our results whether eosinophils of 
varying densities can preferentially generate lipox- 
in A. Nevertheless, it is clear from the results of the 
present study that eosinophil-rich granulocyte 
suspensions can produce lipoxin A without addi- 
tion of exogenous substrates. Results of our 
previous studies suggest hat several independent 
biosynthesis routes may be operative in the forma- 
tion of lipoxins and related compounds [12,18]. 
The biosynthetic route(s) involved in the formation 
of lipoxin A by eosinophil-rich granulocyte sus- 
pensions remain(s) to be identified. Since lipoxin A 
can activate neutrophils [13], constrict lung strips, 
cause changes in microcirculation [ 16,171, activate 
isolated protein kinase C [14] and inhibit human 
natural killer cell function [ 151, the role of eosino- 
phils in its production may be of importance in the 
manifestations observed in HES. 
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